IGFBP3-Targeting Antibodies for TMEM219 Pathway Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for conditions such as inflammatory bowel disease (IBD), type 1 diabetes (T1D), and type 2 diabetes (T2D) are inadequate, as they rely on immunotherapies with adverse effects and limited long-term efficacy, and there are no monoclonal antibodies available to block the IGFBP3/TMEM219 axis, which contributes to cell death and disease progression.
Innovation Solution
Development of antibodies that specifically bind to IGFBP3 without displacing IGF-I and inhibit the IGFBP3/TMEM219 interaction, thereby reducing apoptosis and promoting cell growth and function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunotherapies are used to treat IBD, T1D, and T2D, then disease symptoms are addressed, but adverse effects occur and long-term efficacy is limited
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism (IGFBP3/TMEM219 axis) responsible for beta-cell death and disease progression, rather than using broad-spectrum immunotherapies. By developing monoclonal antibodies that specifically block this axis, the treatment addresses the root cause while avoiding off-target effects of conventional immunotherapies.
Solution Approach 2:
The patent introduces monoclonal antibodies as intermediary molecules that mediate the blocking of the IGFBP3/TMEM219 interaction. These antibodies serve as precise mediators that prevent the harmful signaling pathway without triggering the adverse effects associated with non-specific immunotherapies.
2Reliability
If antibodies that block IGFBP3/TMEM219 binding are developed, then cell death is prevented and beta-cell growth is enhanced, but no such monoclonal antibodies were previously available
Solution Approach 1:
The patent segments the complex immune system into specific targetable components by identifying and isolating monoclonal antibodies that recognize and bind to specific epitopes on the IGFBP3/TMEM219 axis. This segmentation allows for precise targeting of the pathological mechanism while enabling standardized manufacturing of defined antibody products.
3Reliability
If IGFBP3 binding to TMEM219 is blocked, then apoptosis is reduced and beta-cell mass is preserved, but the mechanism involves complex protein-protein interactions
Solution Approach 1:
The patent introduces monoclonal antibodies as intermediary molecules that mediate the blocking of the IGFBP3/TMEM219 interaction. These antibodies serve as precise mediators that prevent the harmful signaling pathway without triggering the adverse effects associated with non-specific immunotherapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively prevent cell death, enhance minigut and beta-cell growth, and improve insulin expression, offering a more targeted therapeutic approach for IBD, T1D, and T2D.
Implementation Method 1
an antibody or antigen binding fragment thereof that binds specifically to IGFBP3 and does not displace the binding of IGF-I to IGFBP3
Data Source
AI summary
The present invention relates to an antibody or antigen binding fragment thereof that binds specifically to IGFBP3 and does not displace the binding of IGF-I to IGFBP3. The antibody inhibits or reduces the binding of IGFBP3 to the TMEM219 receptor. The invention also relates to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.